Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Main objective : evaluation of progression free survival on R-GEMOX and enzastaurin, 1 year after treatment start, in patients with relapsed DLBCL or transformed (CD20+) indolent lymphoma, who are older than 60 years. Patients who are younger than 60 may be included if they are not eligible for HDC followed by ASCT
Critère d'inclusion
- high-risk diffuse large B-cell lymphoma (DLBCL )